VISEN Pharmaceuticals
Latest round
- Series B
Last raised
- Jan 2021
Total raised
- $150M
Investors
- 11
About VISEN Pharmaceuticals
Founded in 2018 and based in Suzhou, China, VISEN Pharmaceuticals is a new drug developer that focuses on endocrine-related therapeutic areas. It has offices in Shanghai, Beijing, Hong Kong, and Taipei. The CEO of the company, Anbang Lu graduated from the Department of Pharmacy, Taipei Medical University. The Company's lead drug, lonapegsomatropin, was IND-approved for a Phase 3 clinical trial in China starting in October 2019, and reached the trial's primary endpoint in May 2022. The company focuses on innovative biopharmaceutical research and development in the field of endocrine-related therapeutics. The product pipeline includes lonapegsomatropin and navepegritide in the field of pediatric endocrinology, and palopegeriparatide in the field of adult endocrinology. Lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years. Navepegritide is used to treat achondroplasia in children aged 2 to 10 years. Palopegteriparatide is used to treat chronic hypoparathyroidism. The company generates revenue by providing innovative biopharmaceuticals in the field of endocrine-related treatment.
Who invested in VISEN Pharmaceuticals
11 investors across 2 rounds
See all investors in VISEN Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VISEN Pharmaceuticals
Who invested in VISEN Pharmaceuticals?
VISEN Pharmaceuticals has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VISEN Pharmaceuticals raised?
VISEN Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did VISEN Pharmaceuticals last raise money?
VISEN Pharmaceuticals's most recent round on record is a Series B, in Jan 2021.
What does VISEN Pharmaceuticals do?
Founded in 2018 and based in Suzhou, China, VISEN Pharmaceuticals is a new drug developer that focuses on endocrine-related therapeutic areas.
Where is VISEN Pharmaceuticals headquartered?
VISEN Pharmaceuticals is headquartered in Suzhou, China.
Which VCs invest in companies like VISEN Pharmaceuticals?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at VISEN Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like VISEN Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.